

Neda Hashemi Sadraei, MD
Ironwood Cancer and Research Centers
Division of Oncology and Hematology
Genitourinary and Lung, Head & Neck Malignancies

Education:

Hematology Oncology Fellowship (07/2017-7/2018)
Indiana University, Indianapolis, IN (Chief Fellow)

Hematology Oncology Fellowship (07/2015-7/2018)
Indiana University, Indianapolis, IN

Internal Medicine Residency (08/2012-7/2015)
University of Texas Health Science Center at Houston, Houston, TX

Neuro- Oncology Research Fellowship (08/2010-6/2012)
National Research Institute of Tuberculosis and Lung
Diseases (NRITLD), Tehran, Iran

Pulmonary Research Fellowship (12/2008-11/2009)
National Research Institute of Tuberculosis and Lung
Diseases (NRITLD), Tehran, Iran

Medical School (12/1996-8/2003)
Iran University of Medical Sciences (IUMS)

Activities and Honors:

Certifications:

Board Certified Medical Oncology & Hematology
American Board of Internal Medicine
Certificate of Educational Commission for Foreign Medical Graduates

Awards and Honors:

Research Mentorship Excellence Award
Ian Rabinowitz Award for Teaching Excellence

Selected Participant
AACR/ASCO Vail Methods in Clinical Cancer Research Workshop, Vail, Colorado.

George and Sarah Jane Fisher Young Investigator Award
\$15,000 research grant awarded by Hoosier Cancer Research Network (HCRN), Indianapolis, IN.

Outstanding Graduating Resident of the Year
University of Texas Health Science Center at Houston, Houston, TX.

Second Place Award, Associate Research Category Poster Competition
American College of Physicians (ACP) Ohio Chapter Meeting, Columbus, OH.

Employee of the Year
Actover Pharmaceutical Company, Tehran, Iran..

Professional Memberships:

American College of Physicians
American Society of Hematology
American Society of Clinical Oncology
Member, American Association for Cancer Research (AACR)

Publications:

Journals Articles

Hashemi-Sadraei N, Einhorn LH, Perkins S, Spinella MJ, Fang F, Hanna NH, Nephew KP, Albany C. Safety and tolerability of guadecitabine (SGI-110) plus cisplatin in patients with platinum-refractory germ cell tumors (GCT): Preliminary results from an open-label phase 1b study. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 1–4, 2018; Chicago, IL. Published in: Journal of Clinical Oncology. 2018;36(suppl): abstr e16545.

Hashemi-Sadraei N, Adra N, Kesler KA, Idrees MT, Boothman DA, Einhorn L. Tissue analysis of NAD(P)H: quinone oxidoreductase (NQO1) and catalase expression in patients with germ cell tumors. Poster presented at the AACR Virtual Annual Meeting II, June 22–23, 2020. Published in Cancer Research 2020; 80(16 Suppl): Abstract 5169.

Gbolahan O, Outlaw DA, Hashemi-Sadraei N, Paluri RV, Williams GR. Impact of time to treatment initiation on real-world (RW) outcomes in metastatic pancreatic cancer (mPC) in the United States. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting Virtual; June 4–8, 2021. Journal of Clinical Oncology. 2021;39(15_suppl):e16254.

Brown J, Kaimakliotis HZ, Kelly WK, Ammons V, Picus J, Walling R, Hashemi-Sadraei N, Fu P, Margevicius SP, Adra N, Garcia JA, McKay RR, Hoimes CJ. HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer. Rapid Abstract Session at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (GU-ASCO), San Francisco, CA, February 16–18, 2023. Journal of Clinical Oncology. 2023;41(suppl 6):abstr 448.

Shilling MW, Hashemi-Sadraei N, Shah SK. Geographic variations in corporate sponsorship for cancer center charity events. Poster presented at the 2024 ASCO Annual Meeting; May 30 – June 3, 2024. Published in Journal of Clinical Oncology. 2024; 42(suppl 16): e23116

Ironwood Cancer and Research Centers, please refer to website for details.